Clinical trials and research studies

This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.

PURPOSE: This is a biological sample collection study aimed at developing an early diagnostic tool for endometrial and ovarian cancer. The investigators are studying the relationship between estrogen driven gynecological cancers, inflammation and the microbiome. Patients who have been diagnosed with endometrial cancer or undergo presurgical evaluation for suspicion of ovarian cancer who are scheduled for a hysterectomy, bilateral oophorectomy and/or salpingectomy are eligible. Control patients undergoing gynecological surgery for benign indications are also being recruited.

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-).

Examining the safety, tolerability, and effectiveness of investigational drug ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia. The study drug will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

This study will evaluate the efficacy, safety, and pharmacokinetics of prasinezumab compared with placebo in patients with early Parkinson's disease (PD).

The primary goals of this study are to determine whether treatment of obstructive sleep apnea with positive airway pressure starting shortly after accute ischemic stroke or high risk TIA (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event and (2) improves stroke outcomes at 3 months in patients who experienced ischemic stroke.